X

Articles

21Sep

Reminder-Bio-Rad Geenius HIV 1/2 Implemented

0 Comments | | Return |

CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.

Read all about it on the Communication page by clicking this link: Communications

 

 

Related

CTS Portland Implements New Laboratory Information System

On April 15, 2019, the New CTS Laboratory Information System has been successfully implemented in Po...

Read More >

CTS Tampa Implementation date change for Ultrio Elite

CTS originally communicated that Tampa will convert from the current Grifols Ultrio Plus NAT triplex...

Read More >

Reminder-CTS Testing Algorithm to be Revised on December 17, 2018

The CTS Medical Advisory Board recently agreed upon a revision to our standard testing algorithm thi...

Read More >

Upcoming HCV Testing Algorithm Change

FDA Guidance titled “Further Testing of Donations that are Reactive on a Licensed Donor Screen...

Read More >

Discontinue HIV-1 IFA Confirmatory Test

CTS received notification from Sanochemia Pharmazeutika AG of their intent to immediately discontinu...

Read More >

MD Revised Headers on CTS forms

Dr. Buff Mair is the new CTS Medical Director and replaces Dr. German Leparc who retired at the begi...

Read More >

Subscribe here to receive CTS updates!

Name